Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
Submitted by
admin
on May 3, 2013 - 12:57pm
Source:
Seeking Alpha
News Tags:
Vical
Amgen
Bristol-Myers Squibb
OncoSec
ImmunoCellular Therapeutics
Roche
NCT00395070
melanoma
Headline:
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
Do Not Allow Advertisers to Use My Personal information
